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HIV-1 Vpr mediates the depletion 
of the cellular repressor CTIP2 to 
counteract viral gene silencing
F. Forouzanfar1, S. Ali1,2, C. Wallet1, M. De Rovere1, C. Ducloy3, H. El Mekdad1, 
M. El Maassarani1, A. Aït-Ammar1,8, J. Van Assche1, E. Boutant4, F. Daouad1,  
F. Margottin-Goguet  5,6,7, C. Moog3, C. Van Lint8, C. Schwartz1 & O. Rohr  1
Mammals have evolved many antiviral factors impacting different steps of the viral life cycle. Associated 
with chromatin-modifying enzymes, the cellular cofactor CTIP2 contributes to HIV-1 gene silencing in 
latently infected reservoirs that constitute the major block toward an HIV cure. We report, for the first 
time, that the virus has developed a strategy to overcome this major transcriptional block. Productive 
HIV-1 infection results in a Vpr-mediated depletion of CTIP2 in microglial cells and CD4+ T cells, two of 
the major viral reservoirs. Associated to the Cul4A-DDB1-DCAF1 ubiquitin ligase complex, Vpr promotes 
CTIP2 degradation via the proteasome pathway in the nuclei of target cells and notably at the latent 
HIV-1 promoter. Importantly, Vpr targets CTIP2 associated with heterochromatin-promoting enzymes 
dedicated to HIV-1 gene silencing. Thereby, Vpr reactivates HIV-1 expression in a microglial model 
of HIV-1 latency. Altogether our results suggest that HIV-1 Vpr mediates the depletion of the cellular 
repressor CTIP2 to counteract viral gene silencing.
Jawed vertebrates including mammals have developed innate and acquired immune responses to fight infections. 
Mammals have evolved many antiviral factors such as SAMHD1 or APOBEC3G that limit virus expression1–3. 
We have reported that the cellular cofactor CTIP2 (Bcl11b) favors the establishment and the persistence of HIV-1 
post-integration latency in microglial cells, the main target of the virus in the brain4–6. CTIP2 works as a scaffold 
protein to recruit at least two different complexes in microglial cells. As part of a chromatin remodelling complex 
CTIP2 is associated with the lysine demethylase LSD1, the histone deacetylases HDAC1 and HDAC2, and the 
histone methyltransferase SUV39H14,7–9. In CD4+ T cells, CTIP2 associates with the NuRD chromatin remod-
elling complex10. In addition to this epigenetic silencing, CTIP2 contributes to control the elongation process of 
gene transcription. Indeed, we found CTIP2 associated with an inactive P-TEFb complex including HEXIM1, 
HMGA1 and the 7SK snRNA11,12. As part of this new complex, CTIP2 represses P-TEFb functions and thereby 
contributes to limit the reactivation of latently integrated HIV-1 proviruses. Altogether, CTIP2 favors the estab-
lishment and the persistence of HIV-1 gene latency in microglial cells, the major reservoirs of virus in the central 
nervous system.
Lentiviruses such as SIV and HIV have developed several mechanisms to evade innate and adaptive immune 
responses. “Accessory” proteins (Nef, Vif, Vpu, Vpx) are encoded by these viruses to allow immune evasion. 
For example, Vpx is involved in the degradation of SAMHD1 via the proteasome pathway (reviewed in13). 
Proteasome-mediated degradation is a privileged pathway subverted by HIV-1 to counteract cellular defenses. 
Associated with a Cul4A-based ubiquitin ligase complex through DCAF1 (VprBP), the HIV-1 accessory protein 
Vpr has long been hypothesized to target an as-yet undiscovered host restriction factor for degradation in order 
to induce G2 arrest14,15. Vpr has been proposed to promote the degradation of cellular factors including UNG216, 
Dicer17, IRF318, ZIP19, the HTLF DNA translocase20 and the post-replication DNA repair factor Exo121. By 
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activation of the SLX4 complex, Vpr prevents an appropriate innate immune response22. Recently, Vpr has been 
shown to repress HIV-1 expression by targeting APOBEC3G23 and an as-yet unidentified macrophage restriction 
factor24. Finally, two recent papers described that the human silencing hub complex (HUSH) is also targeted to 
degradation by Vpr and HIV-2/SIV Vpx25,26. Interestingly, the HUSH complex is presented by the authors as a 
potent restriction factor regulating the transcription step of the viral life cycle.
Here we show that HIV-1 developed a strategy to counteract CTIP2-mediated repression. We report that the 
viral accessory protein Vpr promotes the degradation of CTIP2 through physical and functional interactions with 
the Cul4A-DDB1-DCAF1 complex. Vpr targets CTIP2 associated with the heterochromatin-modifying complex. 
Interestingly, Vpr expression also correlated with a reduced binding of CTIP2 at the HIV-1 promoter and a reac-
tivation of the latent virus in the CHME5-HIV microglial model of latency.
Results
Hiv-1 Expression promotes a vpr-dependent degradation of ctip2. To investigate a possible mod-
ulation of CTIP2 expression in response to HIV-1 infection, we measured its protein and its RNA levels in time 
course experiments in Jurkat T-cells and microglial cells.
Following an initial induction of both CTIP2 mRNA and protein expression after the first 24 h post HIV-
1-infection (Fig. 1, panels A and C), CTIP2 protein expression levels decreased in Jurkat T cells (Fig. 1B WT 
panel) and in microglial cells (Fig. 1D, WT panel) at later time points. Interestingly, while levels of CTIP2 mRNA 
were not affected along the time course (from 24 h to 96 h of infection), deletion of the Vpr gene (Vpr-deleted 
virus - ΔVpr) abrogated CTIP2 depletion upon viral expression (Fig. 1B,D, ΔVpr Panels). To confirm that the 
depletion of CTIP2 mediated by Vpr occurs at a post-transcriptional step, we next overexpressed a FLAG tagged 
CTIP2 in the presence of normalized quantities of WT and ΔVpr proviruses. The WT-, but not the ΔVpr provi-
rus, promoted a depletion of CTIP2 expressed under the control of a CMV promoter (Figure S1). These results 
Figure 1. CTIP2-induced expression in infected cells is counteracted by HIV-1 in a Vpr dependent manner. 
(A,C) Jurkat T cells (A) and Microglial cells (C) were infected with 25 × 103 copies/ml of a VSV-G pseudotyped 
NL4.3ΔEnv-LUC provirus for 24 h. The presence of CTIP2 in infected cells was assessed by western blot and 
the CTIP2 mRNA quantified by RT-Q-PCR. (B,D) Jurkat T cells (B) and Microglial cells (D) were infected 
with 150 × 103 copies/ml of a VSV-G pseudotyped NL4.3ΔEnv-LUC (WT) and a NL4.3ΔEnvΔVpr -LUC 
(ΔVpr) provirus for 24, 48 and 96 h. The presence of CTIP2 in infected cells was assessed by western blot and 
the viral expression was quantified by luciferase assay. The quantifications are presented relative to the quantities 
obtained after 24 h of infection. The results are representative of at least three independent experiments.
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confirmed that CTIP2 expression was impacted post-transcriptionally. Vpr molecules are known to be incorpo-
rated into the virions27. To determine if incoming Vpr proteins are sufficient to induce a depletion of CTIP2 in 
primary cells, we next generated virus-like particles (VLPs) to deliver Vpr in purified CD4+ T cells. As shown 
in Fig. 2A, incoming Vpr induced a significant depletion of CTIP2 in primary CD4+ T cells, suggesting that 
Vpr produced in cells upon HIV-1 replication and Vpr delivered by the virions upon infection reduce CTIP2 
expression. Since CTIP2 has been described to limit the reactivation of latently integrated viruses in microglial 
cells9, we next investigated the impact of incoming Vpr on the CHME5-HIV microglial model of HIV-1 latency. 
Interestingly, Vpr delivery increased by two-fold the number of HIV-1 expressing cells (Fig. 2B). This magnitude 
of reactivation was similar to that obtained with TNFα treatment (Fig. 2B column HA-Vpr vs TNFα). As we 
previously reported that CTIP2 associates with the latent HIV-1 promoter in microglial cells, we next performed 
chromatin IP experiments targeting CTIP2 in the presence or not of Vpr (Fig. 2C). As expected, CTIP2 was found 
associated with the viral promoter but not with the luciferase gene of the construct in microglial cells (Fig. 2C: 
IgG vs (-) mock CTIP2 IP column). However, Vpr expression significantly reduced the binding of CTIP2 (Fig. 2C: 
Vpr vs (-) mock), in line with the previously observed depletion of the protein in nuclear extracts. Vpr has been 
shown to interact directly with the 26 S proteasome and to degrade target cellular factors via the proteasome 
pathway28. We indeed found CTIP2 associated with the 19S subunit of the proteasome but not Vpr (Figure S5). 
To further determine the mechanism underlying CTIP2 depletion, we next treated the cells with the proteas-
ome inhibitor MG132. As shown, MG132 treatment favored CTIP2 binding to the viral promoter (MG132 vs 
(-) mock) and strongly impaired the impact of Vpr (MG132+ Vpr vs MG132). Altogether, these results suggest 
that Vpr produced in cells upon HIV-1 replication and Vpr particles incorporated in virions both contribute to 
the depletion of CTIP2 in cell lines and primary cells. This depletion correlates with reduced binding of CTIP2 
Figure 2. Vpr promotes depletion of CTIP2 in primary CD4+ T cells and at the HIV-1 promoter to induce 
viral reactivation in microglial cells. (A) Relative CTIP2 expression in CD4 T cells was quantified by flow 
cytometry. Expression levels in cells incubated with Virus Like-Particles VLP-HA-Vpr were compared to the 
control VLP-HA particles taken as 1. (B) CHME5-HIV latently infected microglial cell line was infected with 
VPLs or treated by TNFα. The number of GFP+ cells was quantified by flow cytometry and presented relative 
to GFP+ cells obtained after VLP-HA infections. (C) Chromatin Immuno-precipitation experiments targeting 
endogenous CTIP2 at the HIV-1 promoter were performed with chromatin from microglial cells expressing 
the chromatinized LTR-LUC episomal vector and Vpr as indicated. The cells were subjected or not to MG132 
treatment. Enrichments are presented as percentages of the inputs. As a control, the presence of CTIP2 has been 
concomitantly quantified at the luciferase gene region. Results are representative of at least three independent 
experiments.
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at the viral promoter and reactivation of the latent HIV-1. In addition, the impact of MG132 on Vpr-mediated 
depletion of CTIP2 and the interaction of CTIP2 with the 19S subunit of the proteasome suggest an involvement 
of the proteasome pathway and a degradation of the protein rather than translational regulation. To further inves-
tigate Vpr-induced depletion of CTIP2 biochemically, we next expressed increasing amounts of Vpr in CTIP2 
expressing cells. As expected, Vpr expression promoted a dose-dependent depletion of CTIP2 (Fig. 3A). Of note, 
levels of CTIP2 mRNA from control and from CTIP2-overexpressing cells were not significantly affected by 
Vpr (Fig. 3B,C, respectively) confirming the post-transcriptional impact of Vpr on CTIP2 expression. To fur-
ther investigate the involvement of the proteasome pathway, microglial cells were treated with the proteasome 
inhibitor MG132. In accordance with the ChIP results presented in Fig. 2C, MG132 increased the level of endog-
enous CTIP2 expression in nuclear extracts (Fig. 3D, row 7 vs 5), suggesting that the physiological turnover of 
CTIP2 needs a functional proteasome pathway. Again, Vpr reduced CTIP2 expression (Fig. 3D, column 5 vs 1), 
and MG132 impaired Vpr-mediated depletion of CTIP2 (Fig. 3D, column 1 vs 3). These observations strongly 
advocate for a degradation of CTIP2 by the proteasome pathway. To determine if this degradation occurs in 
the nucleus, cells were treated with leptomycin B (LMB), an inhibitor of nuclear export. As shown, LMB treat-
ment did not significantly affect the level of CTIP2 degradation by Vpr (Fig. 3D, column 2 vs 1). We next took 
advantage of the replicates of these experiments to quantify the impact of Vpr on CTIP2 expression levels in the 
presence of LMB and MG132. As shown in Fig. 3E, Vpr promoted a more than two-fold depletion of CTIP2 in 
microglial cells nuclei (first column). However, MG132 abolished the Vpr-mediated depletion of CTIP2 in the 
presence or absence of LMB (two last columns). Altogether, our results suggest that Vpr degrades CTIP2 via the 
proteasome pathway in the nuclei of HIV-1 target cells.
Ctip2 Interacts with the cull4/ddb1-dcaf1 ubiquitin ligase complex. Vpr has been reported to target 
cellular proteins for degradation through recruitment of the Cul4A-DDB1-DCAF1 complex. Since inhibiting the 
proteasome pathway increased CTIP2 expression levels in the absence of Vpr, we first investigated its possible 
interaction with the ubiquitin ligase complex. Confocal microscopy observations were performed on microglial 
cells expressing RFP-CTIP2, GFP-DCAF1, and HA-Vpr alone (Fig. 4A) or in combination (Fig. 4B). As pre-
viously described, CTIP2 is localized in dense- and structured-nuclear domains29. The expression of HA-Vpr 
and GFP-DCAF1 was mainly observed in the nuclear compartment. However, the combined expression of 
Figure 3. Vpr targets nuclear CTIP2 to degradation via the proteasome pathway. (A) Nuclear extracts from 
HEK cells expressing Tap-CTIP2 (t-CTIP2) and increasing amount of GFP-Vpr (g-Vpr) were analyzed by 
western blot for the presence of the proteins indicated. (B,C) CTIP2 mRNA were quantified by RT-Q-PCR in 
the presence or not of Vpr in the absence (B) and in the presence (C) of CTIP2 overexpression. The results are 
presented relative to the pCDNA3 control vector taken as one. (D) Endogenous CTIP2 expression was analyzed 
by western blot in extracts from cells expressing GFP-Vpr or the control GFP and subjected to the indicated 
treatments. Cells were treated with 10 ng/ml leptomycin B for 4 h and then with MG132 (5 μg/μl) for 6 h before 
lysis and nuclear protein extraction. Protein expression was assessed by western blot. (E) Expression of CTIP2 
in the presence of GFP-Vpr was quantified relative to β-actin and presented relative to the quantities obtained in 
the presence of the GFP control protein57. Results are representative of at least three independent experiments.
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RFP-CTIP2 with GFP-DCAF1 promoted a relocation of DCAF1 proteins to CTIP2-induced structures (Fig. 4B, 
upper panel). The yellow staining of the CTIP2-induced structures results from this colocation. Interestingly, Vpr 
expression further turned the staining of CTIP2 structures white, suggesting a triple colocation of Vpr, DCAF1 
and CTIP2 (Fig. 4B, lower panel). We have previously reported that CTIP2 associates with Vpr in CTIP2-induced 
nuclear structures7. To determine whether CTIP2 interacts directly with DCAF1, we next performed fluores-
cence resonance energy transfer (FRET) experiments. As shown in Fig. 4C, the presence of RFP-CTIP2 reduced 
significantly the lifetime of GFP-DCAF1 in the nuclear structures, indicating a direct interaction between these 
two proteins. Surprisingly, the presence of Vpr did not significantly impact on this effect. To confirm the physi-
cal interaction between DCAF1 and CTIP2 biochemically, we performed co-immuno-precipitation experiments 
targeting first CTIP2. DCAF1 and DDB1 were found in association with CTIP2 (Fig. 4D). These associations 
are in accordance with the increased CTIP2 expression observed following MG132 treatment. In addition, we 
found Vpr associated with CTIP2 and the DDB1-DCAF1 complex in nuclear extracts from MG132-treated cells 
(Fig. 4E). These results suggest that Vpr takes advantage of the cellular degradation machinery to deplete CTIP2 
from HIV-1 infected cells and favor HIV-1 expression.
We have reported that CTIP2 associates with two different and exclusive complexes: A complex dedicated 
to epigenetic silencing of gene expression (chromatin modifying enzymes)9 and an inactive form of the P-TEFb 
elongation complex including the 7SK snRNA11. To characterize CTIP2-associated DCAF1 containing com-
plexes, we performed sequential immunoprecipitation (IP) experiments (Fig. 4F). In the first IP that targeted 
DCAF1-associated complexes, we found CTIP2 and HDAC2 (chromatin-modifying enzyme) but not CDK9, 
Figure 4. CTIP2 interacts with the Cull4-DDB1-DCAF1 ubiquitin ligase complex. (A,B) Microglial cells 
expressing RFP-CTIP2, HA-Vpr and GFP-DCAF1 alone (panel A) or in combination (panel B) were subjected 
to confocal microscopy. Scale bars are set to 5 µm. (C) Lifetimes from GFP proteins FRET experiments are 
presented for each condition. The results are representative of 5 independent experiments and from 6 to 10 
quantifications for each condition per experiment. (D,E) Nuclear extracts from cells expressing the proteins 
indicated were subjected to immunoprecipitation experiments targeting Tap-CTIP2 (t-CTIP2) (D) and HA-
Vpr (E). The inputs and the immunoprecipitated complexes were analyzed by western blot. (F) Nuclear extracts 
from cells expressing the proteins indicated were subjected to a first immunoprecipitation targeting FLAG-
DCAF1 (f-DCAF) with anti-FLAG antibodies. The DCAF1 associated complexes were eluted by incubation 
with FLAG peptides and subjected to a second immuno-precipitation targeting CTIP2. The presence of the 
indicated proteins was analyzed at each step by western blot.
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the kinase subunit of the P-TEFb complex. This result suggests that DCAF1 may interact with CTIP2 and its 
chromatin-modifying complex. To confirm that CTIP2, HDAC2 and DCAF1 are part of the same complex, pro-
teins were eluted from the first IP and submitted to a second IP targeting CTIP2. DCAF1 and HDAC2 were found 
associated with CTIP2 in the eluted DCAF1-containing complex, suggesting that CTIP2, DCAF1 and HDAC2 
are members of the same complex (Fig. 4F). Altogether, these results strongly suggest that DCAF1 interacts with 
and degrades CTIP2 bound to the chromatin modifying enzyme complex (HDAC1/2, SUV39H1) but not with 
CTIP2 bound to the inactive P-TEFb complex. This conclusion is in accordance with the degradation of HDAC1 
by Vpr upon HIV-1 infection (Figure S3 and30).
Association with dcaf1 is crucial for vpr-mediated degradation of ctip2. To further characterize 
mechanistically the degradation of CTIP2 by Vpr, we explored whether DCAF1 is needed for the Vpr-mediated 
degradation process by using a Si RNA-based knock-down approach. As expected, depletion of DCAF1 abrogated 
the degradation of CTIP2 (Fig. 5A column 4 vs 2). We next quantified CTIP2 expression levels in the presence 
of WT or mutated Vpr proteins (Fig. 5B). The mutations Q65R (which abrogates DCAF1 binding and G2 arrest) 
and R80A (supports efficient DCAF1 binding but abolishes G2 arrest) were tested14,31,32. As expected, CTIP2 was 
barely detectable in the presence of WT and R80A Vpr proteins (Fig. 5B columns 1 and 3). However, the Q65R 
mutation, abolished Vpr-mediated degradation of CTIP2 (Fig. 5B column 2). These results demonstrated that 
Vpr-mediated G2 arrest does not impact CTIP2 expression and confirmed the requirement for DCAF1 for the 
depletion of CTIP2 by Vpr. Interestingly, upon a strong overexpression of CTIP2, allowing its detection in the 
presence of Vpr, we were able to find WT, R80A and Q65R Vpr proteins associated with CTIP2 (Fig. 5C). Thereby, 
our results suggest that recruitment of DCAF1 is crucial to ensure the Vpr-mediated degradation of CTIP2 but 
dispensable for the physical interactions between the proteins.
Discussion
CTIP2/Bcl11B is involved both in the establishment and the persistence of HIV-1 latency in CD4+ T cells and 
microglial cells8,9,11,33. By silencing integrated HIV-1 proviruses and disfavoring its reactivation, this cellular 
cofactor constitutes a major block to viral expression. To prevent abortive infections, HIV-1 has evolved sophisti-
cated mechanisms to evade innate and adaptive immune responses. Accessory proteins such as Nef, Vif, Vpu, Vpx 
and Vpr are dedicated to some aspects of this immune evasion. Indeed, several restriction factors are targeted to 
degradation by these accessory proteins. Vif targets APOBEC3G23, Vpu targets tetherin by sequestration from the 
site of budding and proteasomal degradation34,35 and Vpx targets SAMHD12. Among the so-called accessory pro-
teins which have to be rather considered as key virulence factors, Vpr remained enigmatic. Vpr is a small protein 
(around 14 kDa) which is involved in several biological functions including nuclear import of the pre-integration 
complex36; envelope protein expression and virion production24; HIV-1 transcription37; post-replication DNA 
repair21, HIV-1 gene splicing38; induction of apoptosis39 and cell cycle arrest22 (reviewed in40). Vpr is produced 
upon HIV-1 replication and a significant amount (275 molecules) is incorporated in the new virion27. We report 
here that Vpr expressed in infected cells (Fig. 1) and incoming-Vpr molecules (Fig. 2) favor the degradation 
of CTIP2 as previously described for the translocase HTLF20. Interestingly, incoming Vpr is necessary to over-
come the HIV-1 transcriptional block observed in dendritic cells41. The influence of CTIP2 in dendritic cells 
has not yet been studied. However, our results suggest that Vpr contributes to unlock CTIP2-mediated blocks 
of HIV-1 gene expression. Vpr has been described associated with the E3 ubiquitin ligase complex to promote a 
Figure 5. DCAF1 binding is necessary for Vpr-mediated degradation of CTIP2. (A) Nuclear extracts from 
control or DCAF1 knock-down cells were analyzed by western blot for the presence of the indicated proteins in 
the presence of GFP-Vpr and the control GFP. CTIP2 expression was quantified relative to the loading control 
using ImageJ software. DCAF1 knock-down efficiency in our experiments is presented. (B) Nuclear extracts 
from cells expressing the indicated proteins were analyzed by western blot. β-actin is presented as a loading 
control. (C) Nuclear extracts from cells expressing large amount of Tap-CTIP2 (t-CTIP2) and the indicated HA-
Vpr proteins were subjected to immunoprecipitation experiments targeting the HA tag. The input and the Vpr-
associated complexes were analyzed for the presence of CTIP2 by western blot.
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proteasome-mediated degradation of cellular targets (for review15). Here we report that CTIP2 interacts with this 
ubiquitin ligase complex via DCAF1/VprBP. Of note, DCAF1 was reported to interact and to protect Vpr from 
proteasomal degradation42. We found Vpr, CTIP2 and DCAF1 co-localized in dense subnuclear structures, and 
FRET studies demonstrated a direct association between CTIP2 and DCAF1. These observations suggested to 
us that Vpr may subvert the proteasome pathway to promote CTIP2 degradation. Interestingly, we showed that 
CTIP2 protein expression is higher in cells treated with MG132 suggesting a physiological regulation of CTIP2 
through the proteasome pathway. Such a CTIP2 protein degradation has been described in a physiological con-
dition such as TCR activation43,44. Therefore, Vpr promotes a constitutive DCAF1-dependent CTIP2 turnover. 
Such a mechanism of action for Vpr has already been described for UNG216 and discussed elsewhere15. In agree-
ment with this, we show that Vpr enhances the ubiquitination of CTIP2 (Figure S2). An increase of the basal 
ubiquitination has already been described for HDAC1 and HDAC3, proteins associated with the formation of 
heterochromatin, the compact-inactive form of the promoters30,45. We further report that Vpr promotes CTIP2 
degradation in the nucleus, at the HIV-1 promoter. This observation strongly argues for an indirect impact of Vpr 
on HIV-1 gene transcription. As a consequence of CTIP2 degradation, Vpr contributes to overcome the transcrip-
tional silencing induced by CTIP2-associated complexes, and to favors Tat function (Figure S4). Interestingly, 
we found CTIP2, HDAC2 and DCAF1 in the same complex. Since P-TEFb is excluded from this complex, our 
results suggest that Vpr promotes the degradation of CTIP2 associated with HDAC1/2 and SUV39H1. The con-
comitant degradation of CTIP2 and HDAC1 (Figure S3) and the recent demonstration that Vpr targets HDAC1 
to a proteasome-mediated degradation further support these conclusions30. Moreover, results of a recent screen 
for factors targeted by the virulence factors Vpr and HIV-2/SIV Vpx strengthen our results25,26. This screen iden-
tified the human silencing hub (HUSH) complex as a new target of Vpr46,47. By the degradation of CTIP2 and 
its associated heterochromatin-promoting enzymes, Vpr unlocks an epigenetic block and activates HIV-1 gene 
transcription. As commented in48, our results suggest a link between the intrinsic immunity and the epigenetic 
control of HIV-1 gene transcription, which might lead to new ways to combat HIV-1.
There are now several pieces of evidence that Vpr is a key virulence factor. It has been shown to disturb several 
cellular pathways including cell cycle arrest (reviewed in40) and DNA repair (reviewed in49). The involvement of 
Vpr in the latter pathway has been associated with the viral escape from innate immune sensing22. We and others 
reported that Vpr is involved in the epigenetic regulation of HIV-1 gene transcription. Vpr promotes the degra-
dation of members of chromatin remodeling complexes such as CTIP2, HDAC130, ZIP and sZIP, the adaptors of 
the NuRD complex19. Interestingly CTIP2 recruits NuRD to silence HIV-1 gene transcription in CD4+ T cells10. 
Recently, we have shown that PKC-mediated phosphorylation on Ser2 of CTIP2 abrogates the recruitment of 
NuRD upon activation via the TCR50. Post-translational modifications drive the association of CTIP2 with differ-
ent complexes and thereby determine CTIP2 functions. Whether or not Vpr is able to discriminate between the 
diverse forms of CTIP2 will require further investigation.
The recognition of Vpr functions in the viral escape from the immune responses in general and in preventing 
HIV-1 latency, as described in the present article, may have profound therapeutic implications51. We have recently 
reviewed the possibilities of targeting post-replication DNA repair complexes to prevent HIV-1 latency52. Taking 
advantage of Vpr-induced depletions of key cellular factors may be an interesting option, as recently described for 
the post replication DNA repair protein Exo121.
Materials and Methods
Plasmids. Most of the constructs used in our assays have been described previously: pcDNA3, pNTAP, 
pFLAG-CTIP2 (f-CTIP2), pRFP-CTIP2, pNTAP-CTIP2 (t-CTIP2) were used8,9,11. pGFP-Vpr WT (g-Vpr), pNL- 
4.3 ∆Env-luc wt, pNL-4.3 ∆Env-luc ∆Vpr19 and pMyc-DDB1 (m-DDB1), pFLAG-DCAF1 (f-DCAF1), pHA- Vpr 
wt, pHA-Vpr Q65R were kindly provided by Dr. F. Margottin-Goguet.
Cell culture. The human microglial (provided by M. Tardieu, Paris, France)53, HEK293T and CHME5-HIV 
cell lines were maintained in Dulbecco’s modified Eagle medium (DMEM) and Jurkat cell line in RPMI 1640. The 
culture mediums were completed with 10% (vol/vol) heat-inactivated fetal bovine serum (FBS) and 100 U/mL 
penicillin/streptomycin. Where indicated, the cells were treated with MG132 (5 μg/μl) for 6 h, 10.0 ng/ml lepto-
mycin B (LMB) for 5 h before harvesting the cells.
Antibodies and reagents. CTIP2 (ab18465) antibodies were purchased from Abcam, BCL11b (A300–
384A) from Bethyl Laboratories, CDK9 (sc-8338), Myc epitope (9 E10), mouse and rat HRP-conjugated from 
Santa Cruz Biotechnology, anti-FLAG M2 affinity gel and β-actin (A5441) from Sigma-Aldrich, and anti-HA.11 
Tag Antibody (AFC-101P) was from Eurogentec. Rabbit HRP-conjugated antibodies were purchased from 
Thermo Fisher Scientific, anti-GFP (632592) from Clontech, and Protein G Magnetic beads from Millipore. 
MG132 and leptomycin B molecules were provided by Sigma-Aldrich, and the protease inhibitor mixture by 
Roche. VprBP (DCAF1) and non-targeting siRNAs were from Dharmacon. SYBR Select Master Mix used for 
Q-PCR was from Thermo Fisher. CTIP2-FITC (25B6) ab123449 and IgG control were purchased from Abcam. 
Anti-HA.11-AF647 was used for the confocal microscopy observations.
HIV-1 infections and viral production in cell lines. The VSV-G pseudotyped ΔEnv-LUC HIV-1 viruses 
were produced by transfecting the pNL4.3 ΔEnv-LUC HIV-1 (WT) or pNL4.3 ΔEnvΔVpr-LUC HIV-1 (ΔVpr) 
constructs together with the VSV-G expression plasmid in 293 T cells. 48 h after transfection, the culture super-
natants were collected and viral production was measured by clinical HIV-1 viral load test (quantification of the 
genomic RNAs).
CTIP2 expression in primary CD4+ T cells infected with VLP. Primary CD4+ T cells were isolated 
and purified from human peripheral blood mononuclear cells (PBMC) of healthy blood donors by positive 
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selection using CD4 MicroBeads selection kits and autoMACS Pro Separator (Miltenyi Biotec) as previously 
described54,55. CD4+ T lymphocytes were activated with phytohemaglutinin A (PHA) (2 µg/ml) (Sigma-Aldrich) 
for 3 days in RPMI 1640 plus Gibco GlutaMAX medium (Thermo Fisher) supplemented with 10% fetal calf 
serum (FCS). Cells were stored frozen. They were thawed the night before use. CD4 T cells were incubated with 
Viral-like particles VLP-HA or VLP-HA-Vpr (obtained from FMG) at 0.1 µg for 0.1 million cells for 1 days. For 
the quantification of intracellular CTIP2 expression, cells were incubated for 10 min at 4 °C with CD3 cell sur-
face molecules before fixation with the Cytofix solution (BD Biosciences) and permeabilized with a solution of 
0.1% Triton X-100. CTIP2 or IgG control isotype were incubated for 30 min at 4 °C. After extensive washing, 
the percentage of CD3-PEC T cells positive for CTIP2 expression was defined by flow cytometry (MACSQuant, 
Miltenyi) and analyzed with Kaluza software.
Co-immunoprecipitation assays and western blotting. Cells cultured in 150-mm diameter dishes 
were transfected using a calcium phosphate co-precipitation method with the plasmids indicated. Lysates were 
prepared two days post-transfection as previously described11. Immunoprecipitations were performed using 
the standard technique, as in11. Finally, the immunoprecipitated complexes were processed for SDS-PAGE and 
immunoblot analysis. Proteins were visualized by chemiluminescence using the SuperSignal Chemiluminescence 
Detection System (Thermo Fisher).
Chromatin immunoprecipitation (ChIP). Cells expressing the chromatinized HIV-1 episomal 
LTR-luciferase construct were subjected to ChIP experiments with IgG control or anti-CTIP2 IgG antibodies, as 
in8,9. The presence of CTIP2 at the promoter- or the luciferase gene- regions was quantified by qPCR. Results are 
presented as percentages of inputs. Values are representative of three independent experiments.
Confocal microscopy. Microglial cells were transfected in 24-well glass-bottomed plates (Greiner Bio-One, 
Ref. 662892) with a DNA mixture containing eGFP-DCAF1, mRFP-CTIP2 or HA-Vpr. At 24 h post-transfection, 
cells were extensively washed, fixed with 4% PFA/PBS solution and kept in 1x PBS at 4 °C until observation with a 
Leica SPE confocal microscope equipped with a Leica 63x1.4NA oil immersion objective (HXC PL APO 63x/1.40 
OIL CS).
Immunofluorescence staining. Microglial cells expressing HA-tagged Vpr were immunodetected as 
described before56. Anti-HA (BioLegend, 901501) was diluted 1/1000 and Alexa Fluor goat anti-mouse (A-21237, 
Thermo Fisher) 1/250. Cells were analyzed by confocal microscopy.
Fluorescence lifetime imaging microscopy (FLIM). Time-correlated single-photon counting FLIM 
was performed on a home-made laser scanning set-up based on an Olympus IX70 inverted microscope with 
an Olympus 60× 1.2NA water immersion objective, as described56. Two-photon excitation at 900 nm was pro-
vided by an InSight DeepSee laser (Spectra Physics). For FLIM, the laser power was adjusted to give count rates 
with peaks up to as few as 106 photons.s−1, so that the pile-up effect can be neglected. Photons were collected 
using a short pass filter with a cut-off wavelength of 680 nm (F75-680, AHF, Germany), and a band-pass filter 
of 520 ± 17 nm (F37-520, AHF, Germany). The fluorescence was directed to a fiber-coupled APD (SPCM-AQR-
14-FC, Perkin Elmer), which was connected to a time-correlated single photon counting module (SPC83, Becker 
and Hickl, Germany). Typically, the samples were scanned continuously for about 60 s to achieve appropriate 
photon statistics to analyze the fluorescence decays. The FRET phenomenon causes a decrease in the fluores-
cent lifetime (τ) of the donor, which can be measured by the FLIM technique at each pixel or group of pixels. 
Experiments were performed with eGFP as a FRET donor and mRFP as acceptor. The FRET efficiency (E) was 
calculated according to: E = 1 − τDA/τD = 1/1 + (R/R0)6 where τDA is the lifetime of the donor in the presence of 
the acceptor and τD is the lifetime of the donor in the absence of the acceptor. A Förster R0 distance (where the 
transfer efficiency is 50%) of 56 Ä was calculated between eGFP used as a donor and mRFP used as acceptor.
Luciferase assays. Microglial cells cultured in 48-well plates were transfected with the indicated vectors and 
the CMV-Renilla luciferase control vector using the calcium phosphate co-precipitation method. Two days later, 
cells were collected and firefly luciferase activity was determined using the Dual-Glo Luciferase Assay System 
(Promega, Madison, WI, USA) and normalized to the Renilla luciferase activity. Values correspond to an average 
of at least three independent experiments performed in triplicates.
mRNA quantification. The total RNA was extracted using an RNeasy Plus Mini Kit (Qiagen, Germantown, 
MD, USA) according to the manufacturer’s instructions. Using SuperScript III Reverse Transcriptase (Thermo 
Fisher) and oligo (dT)12–18 Primers (Thermo Fisher), RNA was reverse transcribed into cDNA. The cDNA 
was diluted 10-fold with DNase-free water. Quantitative PCR was performed on the diluted cDNA using 
SYBR Select Master Mix. Primers used in qPCR include: CTIP2-F 5′-ATTGGAACCTGCCACTTG-3′, 
CTIP2-R 5′-TTTGCCTGTGTTCCACGA-3′ GAPDH-F5′-GAGAAGGCTGGGGCTCATTT-3′, GAPDH-R 
5′-GCAGTGATGGCATGGACTGT-3′. Data were normalized to GAPDH and calculated using the 2−(ΔΔCT) 
method.
Statistical analysis. Data were statistically analyzed by using t tests with Excel (Microsoft) or StatView (SAS 
Institute Inc.). A value of p < 0.05 was considered statistically significant. Results were expressed as S.D. and rep-
resent data from a minimum of three independent experiments.
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